BioCardia
Biocardia Home Helix Biotherapeutic Delivery Morph Access Innovations About Us
Biocardia Enabling Biointerventional Cardiology & Redefining Vascular Access Biocardia Enabling Biointerventional Cardiology & Redefining Vascular Access
BioCardia is a biotherapeutic platform and product company based on fully developed medical device technologies.
Learn More
CORE BUSINESSES

BioCardia is engaged in two core businesses:

Helix Biotherapeutic Delivery offers a catheter system for the local delivery of cells, gene, and protein therapeutics to the heart.

Morph Access Innovations develops advanced catheter products for interventional medicine.

 HELIX NEWS

April 30, 2008
BioCardia and the University of Miami Receive FDA Clearance to Initiate Co-Sponsored Heart Failure Stem Cell Clinical Trial Comparing Two Cell Populations

April 21, 2008
BioCardia Completes $7.4 Million Private Equity Financing: Successful Round Follows Completion of Phase I Clinical Trial Enrollment and Two Year Follow-up Data Publication on First Cohort

more news

 MORPH NEWS

January 2008
A new article has been published in the January 2008 issue of Endovascular Today entitled “Acute-on-Chronic Mesenteric Ischemia. Recanalization of an occluded SMA using a steerable, deflectable guiding catheter.”


more news

 
© 2007 BioCardia, Inc. | 384 Oyster Point Blvd. #5, South San Francisco, CA 94080 | (650) 624-0900 |